Navarro DDA, Acosta CA

Language: Spanish
References: 13
Page: 50-53
PDF size: 210.11 Kb.

Text Extraction

No abstract.

REFERENCES

1. Marin C, Luyten FP, van der Schueren B, Kerckhofs G, Vandamme K. The Impact of Type 2 Diabetes on Bone Fracture Healing. Front Endocrinol. 2018 Jan 9;6. Doi: 10.3389/fendo.2018.00006

2. Lecka-Czernik B. Diabetes, bone and glucose-lowering agents: basic biology. Diabetologia. 2017;60:1163-9.

3. Wongdee K, Charoenphandhu N. Osteoporosis in diabetes mellitus: possible cellular and molecular mechanism. World J Diabetes. 201;2(3):41-8.

4. Lecka-Czernik Beata B. Safety of anti-diabetic therapies on bone. Clin Rev Bone Miner Metab. 2013;1;11(1):49-58.

5. Vianna AGD, Sanchez CP, Barreto FC Review article: effects of type 2 diabetes therapies on bone metabolism. Diabetol Metab Syndr. 2017;9:75. DOI 10.1186/s13098-017-0274-5

6. Vianna AGD, Silva de Lacerda C, Muniz Pechmann L, Garcia Polesel M, Cestari Marino E, Zeghbi Cochenski BV, et al. Vildagliptin has thesame safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial. Diabetol Metab Syndr. 2017;9(1):35. DOI:10.1186/s13098-017-0232-2).

7. Sedlinsky C, Molinuevo MS, Cortizo AM, Tolosa MJ, Felice JI, Sbaraglini ML, Schurman L, McCarthy AD. Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone inrats. Eur J Pharmacol. 2011;668:477-85.

8. McCarthy AD, Cortizo AM, Sedlinsky C. Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy? World J Diabetes. 2016;25;7(6):122-33.

9. Colhoun HM, Livingstone SJ, Looker HC, Morris AD, Wild SH, Lindsay S, et al. and on behalf of the Scottish Diabetes Research Network Epidemiology Group. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia. 2012;55:2929-37.

10. Driessen JHM, Henry RMA, van Onzenoort HAW, Lalmohamed A, Burden AM, Prieto-Alhambra D, et al. Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis. Calcif Tissue Int. 2015;97:104-12.

11. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34(11):2474-6.

12. Mannucci E, Dicembrini I. Drugs for type 2 diabetes: role in the regulation of bone metabolism. Clinical Cases Miner Bone Metab. 2015;12(2):130-4

13. Bunn RC, Uppuganti S, Thompson KIL, Lumpkin CHK, Kalaitzoglou E, Fowlkes JL. The impact of SGLT2 Inhibitors, compared with Insulin, on Diabetic Bone Disease in a mouse model of Type 1. Diabetes Bone. 2017;94:141-51.